Zanosar (Streptozocin) Powder for Solution shortage
Zanosar (streptozocin powders for solution) is on the FDA’s drug shortage list as of Oct 5, 2026. The companies reporting it blame reasons the companies did not specify.
Streptozocin powder for solution is currently in shortage, with the 100 mg/1 mL concentration having no available source right now. The 1 g/10 mL strength still has a listed supply from one manufacturer.
Don’t stop or change your therapy on your own — ask your pharmacist about other companies’ versions and your prescriber about a long-term plan.
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is Zanosar still in shortage? — status as of Oct 5, 2026
Yes, still current as of Oct 5, 2026. 1 of the 2 strengths is still made by at least one company; 1 is not. 1 of the 2 companies that reported this shortage says it still has some supply, and no other company sells the same medicine. Your pharmacy may still need to order it or offer another company’s version.
The charts count only the companies that reported this shortage to the FDA; we could not confirm another company listing it (see below).
Shortage timeline
-
Sep 16, 2026Currently in shortage2 of 2 products affected.
-
Sep 15, 2026FDA refreshed this shortage record1 product updated.
-
Jul 12, 2022First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Zanosar products are affected — by company
Company: ESTEVE PHARMACEUTICALS, S.A. 📞 [email protected] 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Zanosar Powder for Solution, 1 g/10 mL | 1 g/10 mL | Available | — | — |
Company: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Zanosar Powder for Solution, 100 mg/1 mL | 100 mg/1 mL | Unavailable | Estimated recovery: TBD | Other |
These rows are company reports to the FDA for Streptozocin Powder for Solution — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock.
Why is Zanosar in shortage?
Right now, the 100 mg/1 mL vial of Zanosar (streptozocin) made by Teva Pharmaceuticals is unavailable. Unfortunately, Teva hasn't shared a specific public reason for the shortage beyond classifying it as "other," so I can't tell you exactly what's causing the hold-up on their end. There's also no estimated recovery date yet — it's listed as "TBD," meaning to be determined.
The good news is that this report only covers Teva's specific 100 mg/1 mL presentation. The 1 g/10 mL vial of Zanosar from ESTEVE Pharmaceuticals is currently listed as available, so that strength and package size is not affected by this shortage.
Based on the company-reported reason(s) and notes on file with the FDA for Streptozocin Powder for Solution, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take Zanosar?
Streptozocin (also sold as Zanosar) is currently on the FDA drug-shortage list, and I want to walk you through what that means for your treatment.
There are two strengths on this record, and they are in different situations right now. The 1 g/10 mL strength still has an available source from a manufacturer. The 100 mg/1 mL strength has no available source at this time, with an estimated recovery date listed as to-be-determined.
The reported reason is listed only as "other," so there is no further detail on the cause. One of the two manufacturers on this record is still supplying the 1 g/10 mL strength, and this shortage has been ongoing for over a year. That is a long stretch, but it also means pharmacies have had time to learn how to work around it.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- If you take the 1 g/10 mL strength, ask your pharmacy to order it — they can check wholesalers and manufacturers for you.
- If your exact strength cannot be found, ask your prescriber or pharmacist about options, such as using an available strength to make up the dose.
Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles these calls. This is national data and may not match your local pharmacy's stock.
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Therapeutic equivalents & pricing 4 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Quzyttir 10 mg/mL | ESTEVE | 1 vial | — | — | Discontinued |
| Quzyttir 10 mg/mL | TerSera | 1 vial | — | — | FDA listed |
| Quzyttir 10 mg/mL | ESTEVE | 1 vial | — | — | FDA listed |
| Zanosar 100 mg/mL | Teva | 10 ml | — | — | Discontinued |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Zanosar — that fall in the same broad treatment class (antibiotic antineoplastics) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & classification for pharmacists and billers
Where does this data come from?
Other oncology shortages
Zanosar shortage FAQs
Is Zanosar still in shortage?
Which strengths of Zanosar are affected?
Why is Zanosar in shortage?
Which Zanosar products are affected?
When will Zanosar be available again?
Is the brand or the generic affected?
What should I do if I take Zanosar?
Still have a question about the Zanosar shortage?
Ask a pharmacist about this shortage →View Streptozocin Powder, For Solution on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.